{
  "ticker": "ATX",
  "pdf_display_url": "https://www.asx.com.au/asx/v2/statistics/displayAnnouncement.do?display=pdf&idsId=02971953",
  "id": "02971953",
  "pages": 2,
  "price_sensitive": false,
  "date": "20250723",
  "time": "1611",
  "pdf_url": "https://announcements.asx.com.au/asxpdf/20250723/pdf/06m27nsbpzh00n.pdf",
  "summary": "- **Notice under Section 708A(5)(e)**: Issued 1,000,000 shares at $0.135 each due to option exercises.  \n- **Shares rank pari passu** with existing ordinary shares.  \n- **No material capital markets impact** (no new capital raised, no change in structure).  \n\n*Operational details (narmafotinib/ACCENT Trial) omitted as non-material to trading/capital markets.*  \n\n**Conclusion**: No material information for trading or capital markets decisions.",
  "usage": {
    "prompt_tokens": 1223,
    "completion_tokens": 109,
    "total_tokens": 1332,
    "prompt_tokens_details": null
  },
  "model": "deepseek/deepseek-chat-v3-0324:free",
  "processed_at": "2025-07-23T06:18:50.443468"
}